Premium
Early detection of treatment induced cardiac toxicity – can we do better?
Author(s) -
Lombard Janine M,
Paterson Robin
Publication year - 2013
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12085
Subject(s) - trastuzumab , medicine , lapatinib , cardiotoxicity , heart failure , anthracycline , ejection fraction , breast cancer , toxicity , chemotherapy , oncology , cancer , cardiac myocyte , cardiology , pharmacology
Editorial: As the treatment of many malignancies has improved over the last few decades, more than 60% of patients with a new cancer diagnosis will live at least 5 years.1 The early detection and possible prevention of treatment (chemotherapy or targeted therapy)-related toxicity to avoid short- and long-term side effects has thus become increasingly relevant to many patients and their treating physicians